Friday, April 21, 2017

Global mHealth Market Size, Share, Growth, Analysis and Forecast to 2020 | Hexa Research

The Global mHealth Market is poised to expand at a whopping CAGR nearly 50% over the forecast period (2012 to 2020). mHealth or mobile health involves the use of wireless devices and mobiles to offer healthcare services. Despite considerable developments in the field of healthcare services, there are a number of issues that still persist pertaining to affordability and availability. Penetration of smartphones with 4G and 3G networks owing to urbanization & high income levels is expected to fuel the industry in the years to come.

3G & 4G LTE networks facilitate the prompt delivery of telemedicine services via speedy data transfers and video calls. High incidence of chronic diseases, such as diabetes, cancer, and heart ailments can contribute significantly to the global industry in the years to come. Various healthcare mobile applications may help patients in managing and controlling these ailments. However, infrastructural security and data privacy and safety may negatively impact overall demand during the forecast period.

Browse Details of Report@

The worldwide mHealth market is segmented on the basis of services, participants, and geographies. According to services, the divisions are monitoring services, diagnosis services, healthcare systems strengthening services, and others. “Others” mainly pertains to wellness and prevention and thus focuses on geriatric care, smoking de-addiction, drug abuse prevention, healthy living, and child care. In 2013, monitoring services held more than 60% shares in the global market. Such services include independent aging solutions, post acute care services, devices (body trackers) for monitoring vital signs, and chronic disease management. Diagnosis services facilitate effective communications between patients and healthcare professionals about various health related issues.

On the basis of participants, the industry is categorized into healthcare providers, content players, device vendors, and mobile operators. Being a rapidly expanding segment, mobile operators can continue dominating the global market over the forecast period. Beside connectivity services, they also offer end-to-end solutions, mobile telemedicine, content-based wellness information, and health call centers. This segment generates much of its revenues from monitoring & diagnostics services. Device vendors mainly refer to electronics & technology companies that offer equipment for gathering patient medical data and transmit data to back-end servers through mobile networks. Content players deal with information based services either through collaborations or in a stand-alone manner with mobile operators.

Geographically, the global mHealth market is segmented into Asia Pacific, North America, Europe, and Rest of the World. With a market share (in revenue terms) exceeding 30%, North America led the global industry in 2013. Regional drivers are surging demand for monitoring services because of growing prevalence of chronic diseases & ailments worldwide. Asia Pacific can expand robustly at a more than 45% CAGR over the forecast period. The region is fueled by growing need for better healthcare services.

Prominent companies operating in the global industry are Vodafone Group, Samsung Electronics, mQure, Orange, and Allscripts Healthcare Solutions among others. Kaiser Permanente and the Mayo Clinic’s venture capital unit supports an mHealth smoking cessation program that features an online communication & support platform and a wearable that releases drugs at equal time intervals. The concerned platform is undergoing clinical trials for both European and U.S. regulators. It may be available in the market in 2018 or 2019. Commonly known as the “Smartpatch”, this device releases biologically timed drugs. This action is based on the sensors that are present in the patch for measuring vital signs.

Browse Related Category Market Reports @


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Visit Our Blog - hexaresearch1.blogspot.com

Tuesday, April 4, 2017

Interventional Cardiology Devices Market worth $25.2 Billion by 2020 | Hexa Research

The Global Interventional Cardiology Devices Market is anticipated to reach around USD 25.2 billion by 2020. High incidence of heart related disorders can directly impact product demand over the forecast period (2012 to 2020). Valvuloplasty, angioplasty, and coronary thrombectomy are procedures that need such devices. Key industry drivers are popularity of minimally invasive surgeries and unhealthy lifestyles that trigger the onset of cardiovascular anomalies. Also, rising cases of congenital heart diseases may positively impact the overall market in the years to come. The use of novel devices and new drug therapies in treating cardiovascular disorders has led to higher life expectancy and better quality of life of patients. According to the World Health Organization (WHO), number of deaths caused by cardiovascular disorders is expected to be nearly 23.3 million by 2030.

Browse Details of Report@

The worldwide Interventional Cardiology Devices Market is segmented on the basis of products and regions. On the basis of products, the divisions are balloon inflation devices, PTCA balloons, stents, PTCA guidewires, and interventional cardiology catheters. With a market share exceeding 70%, interventional cardiology catheters dominated the global industry in 2013. Application of novel technologies that lower the risks of post-operative complications and restenosis in angioplasty is a key factor that drives this segment. Different types of stents are bio-absorbable, drug eluting, and metal. Bare metal stents have helped in lowering the rates of restenosis by around 20 to 25 percent.

However, owing to greater effectiveness, bio-absorbable & drug eluting stents are increasingly being used in place of bare metal stents. The bio-absorbable stents segment may register the highest growth rate in the forecast period. This is attributed to increasing awareness about the benefits of such stents, such as their ability to lower the possibility of restenosis. Catheters are a rapidly growing product segment because these are utilized extensively in minimally invasive medical procedures. Due to the high incidence of cardiovascular disorders, demand for angioplasty catheters may surge in the forthcoming years. This segment is propelled by technological advancements, widespread patient awareness, and prevalence of structural & congenital heart ailments.

Geographically, the global interventional cardiology devices market is categorized into Europe, North America, Asia Pacific, and Rest of the World. With shares surpassing 35%, North America dominated the overall industry in 2013. Widespread awareness in advanced economies and the presence of large pediatric & geriatric populations are key regional drivers. According to the American Heart Association, nearly 22% of the pediatric population belonging to the 6 to 17 years age group suffers from cardiovascular disorders. This owes to the prevalence of obesity in the region. Asia Pacific can expand at the highest CAGR over the forecast period because of popularity of minimally invasive procedures that ensure quick recoveries and cause minimal trauma to patients.

Key companies in the worldwide interventional cardiology devices industry are Boston Scientific, Abbott Laboratories, Terumo Medical Corporation, B. Braun Melsungen AG, and Cordis Corporation among others. In December 2016, Boston Scientific launched the SYNERGY stent. This product has been approved by the US FDA for use in the treatment of coronary artery disease. It is the first ever stent that offers synchronized polymer & drug absorption. It enables complete & rapid arterial healing and thus lowers the risks of complications pertaining to long term polymer exposure.

Browse Related Category Market Reports @


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Visit Our Blog - hexaresearch1.blogspot.com